Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash flows from operating activities:
Net income (loss)	$ 30,417	$ (16,838)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Change in fair value of warrant liability	(18,609)	2,422
Depreciation and amortization	7,532	10,583
Amortization of deferred financing costs	2,529	2,935
Accretion of debt discount	3,963	3,699
Gain on sale of assets	(2,718)	(1,465)
Stock compensation expense	4,810	4,020
Deferred income tax (benefit) provision	727	(1,492)
Reduction in (excess) tax benefit related to share-based awards	(556)	1,716
Loss on extinguishment of debt	3,225	995
Change in current assets and liabilities:
Accounts receivable	(19,146)	(10,489)
Inventories	(8,470)	49
Accrued liabilities	(5)	2,310
Interest payable	(1,427)	(1,944)
Accounts payable	2,840	1,487
Other current assets	(1,177)	(345)
Income taxes, net	4,187	4,361
Restricted cash		10
Net cash provided by operating activities	8,122	2,014
Cash flows from investing activities:
Capital expenditures	(5,971)	(3,128)
Proceeds from sale of assets	3,765	2,639
Purchase of patents and other intangibles	(243)	(2)
Net cash used in investing activities	(2,449)	(491)
Cash flows from financing activities:
Proceeds from sale of common stock	29,438
Proceeds from exercise of warrants	4,581	69
Debt issuance costs	(1,346)	(2,004)
Repayments of indebtedness	(33,081)	(37,206)
(Reduction in) excess tax benefit related to share-based awards	556	(1,716)
Purchase of treasury stock	(205)	(86)
Proceeds from exercise of stock options	136	3
Proceeds from borrowings		40,000
Net cash provided by (used in) financing activities	79	(940)
Effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency	(120)	(9)
Net increase in cash and cash equivalents	5,632	574
Cash and cash equivalents at the beginning of period	19,863	6,485
Cash and cash equivalents at the end of period	$ 25,495	$ 7,059